Press Releases Year None201920182017 Turning Point Therapeutics to Host Third Quarter 2019 Conference Call Oct 21, 2019 Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor Sep 30, 2019 Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock Sep 05, 2019 Turning Point Therapeutics Announces Proposed Public Offering of Common Stock Sep 03, 2019 Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor Sep 03, 2019 Turning Point Therapeutics To Participate in Upcoming Investor Conferences Aug 28, 2019 Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results Aug 06, 2019 Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference Jul 31, 2019 Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors Jul 31, 2019 Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer Jul 29, 2019 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 27
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor Sep 30, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor Sep 03, 2019
Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results Aug 06, 2019
Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference Jul 31, 2019
Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors Jul 31, 2019
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer Jul 29, 2019
